- Home
- ATHE
as 07-26-2024 4:00pm EST
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
| Founded: | 1997 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 18.6M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 71.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $5.41 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alterity Therapeutics Limited News
ATHE Breaking Stock News: Dive into ATHE Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Alterity Therapeutics to Present at MST Financial Webinar
Zacks
8 days ago
Alterity (ATHE) Up on Interim Data From Advance MSA Study
MT Newswires
9 days ago
Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data
GlobeNewswire
10 days ago
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
GlobeNewswire
a month ago
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
GlobeNewswire
2 months ago
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
GlobeNewswire
3 months ago
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
GlobeNewswire
3 months ago
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Compare ATHE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHE Alterity Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.